Coherus BioSciences Inc
(NASDAQ:CHRS)
$8.42
0.02[0.24%]
At close: Feb 7
$8.42
After Hours: 4:01PM EDT
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.

Loading...
Day Range8.160 - 8.45052 Wk Range5.581 - 14.110Open / Close8.410 / 8.420Float / Outstanding61.490M / 77.778M
Vol / Avg.588.065K / 1.270MMkt Cap654.890MP/E-50d Avg. Price7.990
Div / Yield (Forward)- / -%Payout Ratio-Total Float61.490MEPS-3.590
Globe Newswire - May 5, 2022, 4:01PM
Seeking Alpha - Jan 9, 2023, 8:00AM
Seeking Alpha - Dec 23, 2022, 3:12PM
Seeking Alpha - Dec 23, 2022, 8:34AM
Seeking Alpha - Nov 7, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2023-05-04
REV
Q4 2022Est.ActualSurprise
EPS-0.690

(EXPECTED) 2023-02-21

REV48.380M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Coherus BioSciences (CHRS) stock?

A

You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Coherus BioSciences's (CHRS) competitors?

Q

What is the target price for Coherus BioSciences (CHRS) stock?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Coherus BioSciences (CHRS)?

A

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.

Q

Does Coherus BioSciences (CHRS) pay a dividend?

A

There are no upcoming dividends for Coherus BioSciences.

Q

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

A

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.

Q

Is Coherus BioSciences (CHRS) going to split?

A

There is no upcoming split for Coherus BioSciences.

Q

What sector and industry does Coherus BioSciences (CHRS) operate in?

A

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.